Insider · CIK 0001920545
Matthias Bodenstedt
Files at MLTX (MoonLake Immunotherapeutics). First filing Oct 9, 2025, latest Jun 23, 2026.
In brief
Matthias Bodenstedt files SEC Form 4 as CFO at MLTX (MoonLake Immunotherapeutics). Since Oct 9, 2025, Matthias Bodenstedt has reported 1 open-market buy worth $99k and 5 open-market sells worth $3.2M, the latest filed on Jun 23, 2026.
A track record needs three past buys with six months of prices behind them; Matthias Bodenstedt has 0, so none is measured yet.
The newest scored trade: sold $862k of MLTX on Jun 22, 2026, filed Jun 23, 2026, scored 40 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 5 sells worth $3.2M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MLTX: MoonLake Immunotherapeutics
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | MoonLake Immunotherapeutics | $862k 39,120 shares | -3% | +255% from low-64% from high | |
| 32Weak | MoonLake Immunotherapeutics | $352k 17,876 shares | -2% | +207% from low-69% from high | |
| 15Weak | MoonLake Immunotherapeutics | $273k 13,653 shares | -1% | +202% from low-70% from high | |
| 23Weak | MoonLake Immunotherapeutics | $47k 2,426 shares | -0% | +201% from low-70% from high | |
| 42Moderate | MoonLake Immunotherapeutics | $1.7M 87,795 shares | -7% | +211% from low-69% from high | |
| 32Weak | MLTXbuy MoonLake Immunotherapeutics | $99k 10,870 shares | +2% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 9, 2026 | MLTX MoonLake Immunotherapeutics | 160,870 0.22% of outstanding | $3.0M | Apr 9, 2026 | none |
| Dec 20, 2023 | MLTX MoonLake Immunotherapeutics | 5,264 0.01% of outstanding | $312k | Dec 20, 2023 | $5.6M |
| Dec 19, 2023 | MLTX MoonLake Immunotherapeutics | 94,736 0.16% of outstanding | $5.6M | Dec 19, 2023 | none |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -39,120 | $22.04 | $862k | 1,115,435 | Jun 23, 2026 |
| Jun 17, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -15,082 | $19.68 | $297k | 1,157,349 | Jun 18, 2026 |
| Jun 18, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -2,794 | $19.60 | $55k | 1,154,555 | Jun 18, 2026 |
| May 11, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -13,653 | $20.02 | $273k | 1,172,431 | May 13, 2026 |
| Apr 14, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -2,426 | $19.56 | $47k | 1,186,084 | Apr 16, 2026 |
| Apr 9, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -85,870 | $18.94 | $1.6M | 1,190,435 | Apr 10, 2026 |
| Apr 10, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -1,925 | $19.51 | $38k | 1,188,510 | Apr 10, 2026 |
| Jan 7, 2026 | MLTX MoonLake Immunotherapeutics | AGrant or award Class A ordinary shares, par value $0.0001 per share | +354,296 | $0.00 | $0 | 1,276,305 | Jan 9, 2026 |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | CConversion Class A ordinary shares, par value $0.0001 per share | +294,473 | - | - | 922,009 | Dec 22, 2025 |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | DDisposition to issuer Class C ordinary shares, par value $0.0001 per share | -294,473 | - | - | 0 | Dec 22, 2025 |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | CConversion Common shares, par value CHF 0.10 per share, of MoonLake AGderivative | -8,754 | - | - | 0 | Dec 22, 2025 |
| Oct 8, 2025 | MLTX MoonLake Immunotherapeutics | POpen-market purchase Class A ordinary shares, par value $0.0001 per share | +10,870 | $9.09 | $99k | 627,536 | Oct 9, 2025 |
| Feb 27, 2025 | MLTX MoonLake Immunotherapeutics | AGrant or award Class A ordinary shares, par value $0.0001 per share | +95,763 | $0.00 | $0 | 616,666 | Mar 3, 2025 |
Questions about Matthias Bodenstedt
Answered from the filings on this page, as of the latest one.
Is Matthias Bodenstedt buying or selling?
In the last 12 months Matthias Bodenstedt reported 0 open-market buys worth $0 and 5 open-market sells worth $3.2M on SEC Form 4; the latest was sold $862k of MLTX on Jun 22, 2026. Grants, option exercises and tax withholding are not counted.
How did Matthias Bodenstedt's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matthias Bodenstedt has 0.
Where does Matthias Bodenstedt file Form 4?
Matthias Bodenstedt has filed Form 4 at MLTX (MoonLake Immunotherapeutics) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.